Literature DB >> 9170008

Role of vasopressin in essential hypertension: racial differences.

G Bakris1, M Bursztyn, I Gavras, M Bresnahan, H Gavras.   

Abstract

BACKGROUND: Arginine vasopressin (AVP), in addition to being an antidiuretic hormone, might also have pressor effects relevant to the maintenance of hypertension. Results from several experimental and clinical studies suggested that the pressor function of AVP is more important in low-renin hypertension and in the salt-loaded state and that it might be further maximized under sympathetic suppression.
OBJECTIVE: To assess whether selective vasopressin receptor inhibition lowers the blood pressure in a racially diverse group of low-renin hypertensive subjects.
METHODS: Thirty-nine hypertensive subjects (16 Caucasian, 23 African-American) eating a 200 mmol/day sodium diet were administered a single intravenous dose of a selective vasopressin receptor antagonist and their blood pressure was monitored constantly for the ensuing 3 h. The protocol was repeated 3 days later after treatment with a single oral dose of 0.4 mg clonidine.
RESULTS: Of these patients, 54% had their blood sampled for determination of hormone profiles. African-Americans with hypertension had higher baseline plasma AVP levels than did Caucasians (1.13 +/- 0.05 versus 0.37 +/- 0.06 pg/ml, respectively, P < 0.05), and lower plasma renin activity (0.34 +/- 0.07 versus 1.03 +/- 0.08 ng/ml per h, respectively, P < 0.05). Selective vasopressin receptor inhibition lowered the mean arterial pressure in African-Americans but not that in Caucasians (lowering by 28 +/- 4 mmHg in African-Americans versus lowering by 5 +/- 3 mmHg in Caucasians, P < 0.05). Moreover, vasopressin receptor blockade further reduced the arterial pressure in African-Americans but not that in Caucasians after pretreatment with clonidine.
CONCLUSION: AVP seems to play a more important role as a pressor hormone in maintaining the elevation of arterial pressure in African-American hypertensives than it does in Caucasian hypertensives.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9170008     DOI: 10.1097/00004872-199715050-00011

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  29 in total

Review 1.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

2.  Influence of age and sex on signal intensities of the posterior lobe of the pituitary gland on T1-weighted images from 3 T MRI.

Authors:  Asako Yamamoto; Hiroshi Oba; Shigeru Furui
Journal:  Jpn J Radiol       Date:  2012-12-26       Impact factor: 2.374

3.  Race, sex, and the regulation of urine osmolality: observations made during water deprivation.

Authors:  Michael L Hancock; Daniel G Bichet; George J Eckert; Lise Bankir; Mary Anne Wagner; J Howard Pratt
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-06-23       Impact factor: 3.619

Review 4.  Role of angiotensin III in hypertension.

Authors:  Annabelle Reaux-Le Goazigo; Xavier Iturrioz; Celine Fassot; Cedric Claperon; Bernard P Roques; Catherine Llorens-Cortes
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

5.  Vasopresin and human hypertension.

Authors:  Alberto Del Bo
Journal:  Cell Mol Neurobiol       Date:  2003-10       Impact factor: 5.046

6.  Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.

Authors:  Masahiko Oguro; Yuta Kogure; Junichi Hoshino; Yoshifumi Ubara; Hiroki Mizuno; Akinari Sekine; Masahiro Kawada; Keiichi Sumida; Rikako Hiramatsu; Eiko Hasegawa; Masayuki Yamanouchi; Noriko Hayami; Tatsuya Suwabe; Naoki Sawa; Kenmei Takaichi
Journal:  J Nephrol       Date:  2018-10-24       Impact factor: 3.902

7.  Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent.

Authors:  Nicole K Littlejohn; Rick B Siel; Pimonrat Ketsawatsomkron; Christopher J Pelham; Nicole A Pearson; Aline M Hilzendeger; Beth A Buehrer; Benjamin J Weidemann; Huiping Li; Deborah R Davis; Anthony P Thompson; Xuebo Liu; Martin D Cassell; Curt D Sigmund; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-27       Impact factor: 3.619

8.  Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis study.

Authors:  Charles X Kim; Kent R Bailey; George G Klee; Allison A Ellington; Guanghui Liu; Thomas H Mosley; Hamid Rehman; Iftikhar J Kullo
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

9.  Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension.

Authors:  Marie-Claude Fournie-Zaluski; Celine Fassot; Bruno Valentin; Dragan Djordjijevic; Annabelle Reaux-Le Goazigo; Pierre Corvol; Bernard P Roques; Catherine Llorens-Cortes
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-10       Impact factor: 11.205

10.  Vasopressin directly regulates cyst growth in polycystic kidney disease.

Authors:  Xiaofang Wang; Yanhong Wu; Christopher J Ward; Peter C Harris; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2007-11-21       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.